Stockscreener 앱 받기
2.115
0.24%
-0.005
전일 마감가:
$2.12
열려 있는:
$2.19
하루 거래량:
42,946
Relative Volume:
0.03
시가총액:
$28.51M
수익:
-
순이익/손실:
$-30.16M
주가수익비율:
-6.2206
EPS:
-0.34
순현금흐름:
$-39.49M
1주 성능:
-6.00%
1개월 성능:
+0.24%
6개월 성능:
-28.06%
1년 성능:
-36.87%
1일 변동 폭
$2.10
$2.19
1주일 범위
$2.095
$2.30
52주 변동 폭
$1.83
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
명칭
Dare Bioscience Inc
전화
858-926-7655
주소
3655 NOBEL DRIVE, SAN DIEGO, CA
DARE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.115 | 28.58M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.28 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.63 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.19 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
800.57 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
328.93 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Dare Bioscience Inc 주식(DARE)의 최신 뉴스
Daré Bioscience receives $4 million grant installment for contraceptive device By Investing.com - Investing.com Nigeria
Daré Bioscience Receives $4 Million Non-Dilutive Grant - GlobeNewswire
Dare Bioscience (DARE) Secures $4M for Long-Acting Contraceptive Development - GuruFocus
Daré Bioscience receives $4 million grant installment for contraceptive device - Investing.com India
$41.8M Received to Date — Daré Bioscience Advances DARE-IDDS Contraception Program, Seeks Partners - Stock Titan
Daré Bioscience enters into $15M stock purchase agreement - MSN
Dare Bioscience risks Nasdaq delisting over market value - MSN
DARE Secures Gates Foundation Funding for Preeclampsia Projects - GuruFocus
Daré Bioscience, Inc. Secures $499,000 Grant from Gates Foundation to Address Preeclampsia in Women's Health - Quiver Quantitative
Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research - GlobeNewswire
76,000 Maternal Deaths Annually: Daré Bioscience Receives Gates Grant to Combat Preeclampsia Crisis - Stock Titan
Dare Bioscience (NASDAQ:DARE) Shares Pass Below 200 Day Moving Average – What’s Next? - Defense World
Daré Bioscience targets Q4 2025 launch for DARE to PLAY Sildenafil cream while advancing dual-path strategy - MSN
Dare Bioscience files to sell 2.75M shares of common stocks by selling shareholders - MSN
What’s the recovery path for long term holders of Daré Bioscience Inc.Inflation Watch & Low Drawdown Investment Ideas - newser.com
Using Python tools to backtest Daré Bioscience Inc. strategies2025 Price Action Summary & Comprehensive Market Scan Insights - Newser
Maxim upgrades Daré Bioscience on extended cash runway, commercial launch - TradingView
Maxim Group upgrades Dare Bioscience stock to Buy on funding boost - Investing.com Canada
Dare Bioscience (DARE) Upgraded to Buy by Maxim Group | DARE Sto - GuruFocus
Dare Bioscience shares rise 4.37% premarket after Maxim upgraded to Buy from Hold. - AInvest
Dare Bioscience: Maxim Group upgrades Buy from Hold, PT $8. - AInvest
Maxim Upgrades Dare Bioscience to Buy From Hold, Price Target is $8 - MarketScreener
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Daré Bioscience Engages Market with New Presentation - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2025 Earnings Call Transcript - MSN
Pattern recognition hints at Daré Bioscience Inc. upsideQuarterly Trade Review & Long-Term Safe Investment Ideas - Newser
Brookline Capital Markets Sticks to Their Buy Rating for Daré Bioscience (DARE) - The Globe and Mail
Dolliver Maintains Buy Rating on Daré Bioscience with $11 Price Target - AInvest
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates - MSN
Dare Bioscience stock price target lowered to $11 at Brookline Capital - Investing.com Canada
Daré Bioscience's Strategic Growth and Market Expansion Ahead of Sildenafil Cream Launch - AInvest
Daré Bioscience: Strategic Growth and Market Expansion with Upcoming Sildenafil Cream Launch - TipRanks
Dare Bioscience shares fall 3.55% after-hours following Q2 2025 earnings call. - AInvest
Dare Bioscience 2025 Q2 Earnings Net Loss Widens Sharply - AInvest
Dare Bioscience 2025 Q2 Earnings Sharp Net Loss Deteriorates 131% - AInvest
Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Daré Bioscience Announces Q2 2025 Financial Results - TipRanks
Daré Bioscience Q2 2025 Earnings Call: Financial Results and Business Update - AInvest
Daré Bioscience's Q2 2025: Diverging Paths in Marketing, Financial Health, and R&D Investment - AInvest
Daré Bioscience's Q2 2025 Earnings: A Strategic Inflection Point in Women's Health Innovation - AInvest
Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings call transcript: Dare Bioscience Q2 2025 reports cash boost, product updates - Investing.com Canada
Transcript : Daré Bioscience, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool
Daré Bioscience Readies First Commercial Product Launch as Multiple Women's Health Solutions Near Market - Stock Titan
Dare Bioscience Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Dare Bioscience (DARE) down more than 70% since Jul 14 - AInvest
Daré Bioscience to Host Second Quarter 2025 Financial - GlobeNewswire
Dare Bioscience Inc (DARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
2.69%
자본화:
|
볼륨(24시간):